Clinical trial
Effects of FT011 in Systemic Sclerosis
NCT04647890 · Certa Therapeutics, Industry · Completed
Key facts
| NCT number | NCT04647890 |
|---|---|
| Title | Effects of FT011 in Systemic Sclerosis |
| Official title | A Phase II, Randomised, Double Blind, Placebo-controlled Study of the Pharmacokinetics, Pharmacodynamic Effects, and Safety, of Oral FT011 in Participants With Diffuse Systemic Sclerosis |
| Lead sponsor | Certa Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Scleroderma, Systemic, Diffuse, Sclerosis |
| Intervention type | Drug |
| Interventions | FT011, Placebo |
| Enrollment | 30 |
| Start date | Jul 19, 2021 |
| Primary completion | Oct 12, 2022 |
| Completion | Nov 16, 2022 |
| First posted | Dec 1, 2020 |
| Last update posted | Dec 20, 2023 |
| Countries | Australia, Netherlands, Poland, Spain, Ukraine |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: